Loading...

KYNB KYNTRA BIO INC Product Launches 8-K Filing

KYNT

KYNB

KYNTRA BIO INC

(KYNB)

2023 8-K

Financial Results Report

Compliance Notification

Financial Results Released

Company Name Change

Financial Results Released

Payment Received

Asset Sale Completed

Acquisition Announcement

Financing Agreement Update

Debt-Equity Swaps

Divestment of Assets

Reverse Stock Split

Financial Statements

Bylaw Amendment

Drug Publication

Agreement Amendments

Financial Update

Equity Offering

Management Change

Q3 Financial Results

Lease Termination

Director Resignations

Executive Departures

Restructuring Plan

Financial Results and Busin...

Investor Presentation

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Delisting Notice

Appointment of CEO and Dire...

Resignation of Chief Medica...

Financial Results Announcement

Appointments, resignations

Management changes

Annual Meeting of Stockholders

Positive Results from Phase...

Financial Results Announcement

Financing Agreement

External Links:

FibroGen, Inc. announced topline results from its Phase 3 study of pamrevlumab for the treatment of Duchenne muscular dystrophy in non-ambulatory patients.

AI Assistant

KYNTRA BIO INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.